Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Summary

To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.

Timeline

Start

2016-03-14

Primary completion

2024-02-22

Completion

2024-02-22

Drugs

Indications